The FLT3 inhibitors market is currently established. With their respective therapeutic portfolios developed and created specifically for the treatment of FLT3 mutated acute myeloid leukaemia, a large number of new and established companies are entering the market, which is causing the industry's massive growth in the treatment of blood cancers with FLT3 positive mutations (AML). Through...